PROKIDNEY CP (PROK)
(Delayed Data from NSDQ)
$2.12 USD
-0.59 (-21.77%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.12 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
ProKidney Corp. (PROK) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.33 | $18.00 | $2.00 | 207.38% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for ProKidney Corp. comes to $8.33. The forecasts range from a low of $2.00 to a high of $18.00. The average price target represents an increase of 207.38% from the last closing price of $2.71.
Analyst Price Targets (6 )
Broker Rating
ProKidney Corp. currently has an average brokerage recommendation (ABR) of 1.57 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.57 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, five are Strong Buy, representing 71.43% of all recommendations. A month ago, Strong Buy represented 71.43%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
1/7/2024 | BTIG | Justin R Zelin | Strong Buy | Strong Buy |
8/1/2023 | Evercore Partners | Jonathan Miller | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.57 |
ABR (Last week) | 1.57 |
# of Recs in ABR | 7 |
Average Target Price | $8.33 |
LT Growth Rate | 37.50% |
Industry | Medical - Drugs |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -0.25 |